Context Therapeutics Inc. (CNTX) Stock Profile — Insider Trades & Financials

Net Income-$13.0M

EPS$-0.24

Market Cap$242.6M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Martin Lehr

CEO & Executive Director

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Founded: 2015
Employees: 12
Headquarters: Philadelphia, Pennsylvania, United States
Website

⚡

Core Efficiency

ROE?

-21.54%

ROA?

-19.02%

D/E Ratio?

0.13

📊

Profitability Ratios

Current Ratio?

8.52

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Sep 8, 2026 (in 152 days)

Annual Report (10-K) — Based on filing pattern

Sep 8, 2026

Predicted10-K

Mar 23, 2026

10-KQ4 20254d after period end

Mar 23, 2026

10-KFY 202582d after period end

Nov 5, 2025

10-QQ3 20251d after period end

Aug 6, 2025

10-QQ2 20252d after period end

May 7, 2025

10-QQ1 20252d after period end

Mar 20, 2025

10-KQ4 20242d after period end

Mar 20, 2025

10-KFY 202579d after period end

Nov 6, 2024

10-QQ3 20242d after period end

Loading company sections...

Context Therapeutics Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness